Zealand Pharma Shares Slide on Trial Dropouts
Zealand Pharma shares dropped after nearly one in five patients quit a late-stage survodutide trial due to side effects. The data raised fresh investor concerns regarding dropout rates for the obesity drug developed with Boehringer Ingelheim.
Xurve View
Insights:
Xurve View
ZEALAND PHARMA A/S shares fell 13% on Thursday after trial data showed nearly one in five patients quit late-stage survodutide trials due to gastrointestinal side effects. It is the second time this year that dropout concerns have hit the Denmark-based drugmaker. The obesity drug, developed in partnership with Boehringer Ingelheim, faces scrutiny over tolerability.
